about
Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisImpact of Exercise on Innate Immunity in Multiple Sclerosis Progression and SymptomatologyChemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of actionMitoxantrone-Surfactant Interactions: A Physicochemical OverviewDevelopment of oral immunomodulatory agents in the management of multiple sclerosisMitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosisAdenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-regionTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase.Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly.Daclizumab treatment for multiple sclerosis.T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.Saccharomyces cerevisiae as a model system to study the response to anticancer agents.Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choicesParallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.Development of a fluorescence resonance energy transfer-based intracellular assay to identify novel enterovirus 71 antivirals.Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of SapacitabineInfluence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study.A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?Disease Modifying Therapy in Multiple Sclerosis.Combination therapies in multiple sclerosis.Current and future disease-modifying therapies in multiple sclerosis.The potential role of B cell-targeted therapies in multiple sclerosis.Current disease-modifying treatment of multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.The benefits and detriments of macrophages/microglia in models of multiple sclerosisDisease modification in multiple sclerosis: an update.Anthraquinones As Pharmacological Tools and Drugs.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.
P2860
Q24185806-6E7AE863-DFA0-46EB-86B6-21AEA1B6CDB9Q24187126-0E75B2AC-12D4-4FC0-ACDF-EA9F67C5E9E9Q24188270-E3447CCD-795E-4AF5-9C72-CE2B7671E5D5Q24202108-40EA9864-0470-447D-8736-8B0BF80E0EEDQ24235249-52BFA9CD-4581-4B86-810E-FC7802001381Q26745562-D653E052-0415-4575-B4AE-B2F6D1346CB5Q27693179-CD70F9FD-FD26-4CEB-B3B6-9C6345BD1201Q28066259-4C44442D-B5D6-47D3-A53C-C74496A897E5Q28388704-8B79A504-E6B1-4991-80E1-7E560635D872Q28480940-A96298C5-5D86-47E7-819B-150429910C4AQ28484203-36318F4F-EC88-4B04-8003-2C36A1047C52Q30234672-6801F1E3-2F98-474C-A4AF-BE8D8DC0B6DEQ30976460-59A0A805-06CA-4CEE-B4EA-C6D42AF67DC3Q31014036-AF2B2A4D-AFC4-4C43-BCC7-AB179DA1EFC6Q33302240-5E296896-B3C8-4D51-8E4A-708630641FE5Q33382919-A235608E-C84B-4631-893C-39A21032764DQ33723154-021AED6F-454B-4037-B013-D0997375012FQ34230150-B563ACE1-3D6F-4657-98B9-FC4DBE5F39ADQ34291657-2F4776AB-AB4E-45B0-A2BA-162D9152AE24Q34771798-41EB938A-1F36-44BD-AD5E-C9CA22B7FE71Q34852971-49506F87-5236-4B01-B438-12628DFC17CEQ35151856-89953D31-DE11-451F-87E4-132DE7F5CD78Q35570425-20E2B3C8-BFC6-47B5-890C-9E86ADD222D2Q35738585-4B5A489B-A606-461F-8811-F60D016978C1Q36200660-78099D9C-B209-4991-A5C9-6C323D5E1BE3Q36289307-32A221C1-3B93-4B10-9E39-1AB7BC9FCE08Q36305638-9CF01957-1E07-4F20-9665-0601E8A65A01Q36924922-F7826D70-3497-4670-9477-B81D626FBBF2Q36979819-5F6DA5FC-FC0A-43C1-8F86-740E64E5EA52Q37101300-C760A9CE-C17F-47CF-80D8-2F3B85AAD92FQ37747735-6A380BAD-6DBC-42D2-87B2-7854DD8D7664Q37818131-F99E676C-E7A5-424F-908B-1BF09ECA22DFQ37855719-E29F76D1-38E3-4DD1-AEE4-FCEB8C14C8B6Q38083041-7B50B792-C111-461D-9BA1-867B8052D0D2Q38120527-958154DB-70FC-4CD2-B738-770FABBA09A0Q38150823-623DC97B-6C3E-4E80-9A42-B79AEB3CD0C8Q38816745-62C3B939-B902-4FB3-A4BF-7E3E77CA1151Q38946338-FFA8D739-FB81-4238-A2CE-59C5CAFD3602Q39021942-DE805377-F948-451D-B2A0-4ABC1B96CF1EQ42501446-2BA16522-76EF-4667-8C01-15DEDAD030E1
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Mechanism of action of mitoxantrone.
@ast
Mechanism of action of mitoxantrone.
@en
type
label
Mechanism of action of mitoxantrone.
@ast
Mechanism of action of mitoxantrone.
@en
prefLabel
Mechanism of action of mitoxantrone.
@ast
Mechanism of action of mitoxantrone.
@en
P1433
P1476
Mechanism of action of mitoxantrone.
@en
P2093
Edward J Fox
P356
10.1212/WNL.63.12_SUPPL_6.S15
P407
P433
12 Suppl 6
P577
2004-12-01T00:00:00Z